Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain

被引：0
作者：
F. Javier Jiménez
Pilar Guallar-Castillón
Carlos Rubio Terrés
Eliseo Guallar
机构：
[1] Unidad de Investigación,Research Unit
[2] Fundación Jiménez Díaz,Centro Universitario de Salud Pública
[3] Universidad Autonoma de Madrid,Scientific Department
[4] Wyeth-Lederle,Department of Epidemiology and Biostatistics
[5] National School of Public Health,undefined
来源：
PharmacoEconomics | 1999年 / 15卷
关键词：
Adis International Limited; Haemophilus Influenzae; Vaccination Programme; Invasive Disease; Haemophilus Influenzae Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need to perform an economic evaluation of its use. The objective of this study was to evaluate the costs and benefits of introducing a universal vaccination programme for children under 1 year of age in Spain.
引用
收藏
页码：75 / 83
页数：8
相关论文
共 80 条
[1]  
Shapiro ED(1991)The epidemiology and prevention of disease caused by Epidemiol Rev 13 113-42
[2]  
Ward JI(1993) type b JAMA 269 221-6
[3]  
Adams WG(1977)Decline of childhood Pediatrics 60 730-7
[4]  
Deaver KA(1984) type b (Hib) disease in the Hib vaccine era N Engl J Med 310 1561-6
[5]  
Cochi SL(1991) type b capsular polysaccharide vaccine in children: a doubleblind field study of 100,000 vaccinees 3 months to 5 years of age in Finland Pediatr Infect Dis J 10 97-104
[6]  
Peltola H(1991)Prevention of Pediatr Infect Dis J 10 92-6
[7]  
Käyhty H(1992) type b bacteremic infections with the capsular polysaccharide vaccine J Pediatr 121 355-62
[8]  
Sivonen A(1993)Efficacy in infancy of oligosaccharide conjugate Pediatrics 92 272-9
[9]  
Peltola H(1994) type b (HbOC) vaccine in a United States population of 61.080 children Bol Epidemiol Microbiol 2 23-4
[10]  
Käyhty H(1993)Safety and immunogenicity of oligosaccharide conjugate Enferm Infecc Microbiol Clin 11 19-28
12345678